Aclaris Therapeutics

Moat components today are weak because Aclaris has no approved products. Intangible assets: 35/100. The company holds ex‑Greater China licenses to bosakitug (ATI‑045) and bispecific ATI‑052, plus internal ITK assets and discovery know‑how, but these are early and licensed rather than owned outright.

Obligations include up to 920 million dollars in milestones and low‑to‑mid single‑digit royalties to Biosion. Switching costs: 10/100. In immunology, prescriber and payer switching costs are modest unless a product demonstrates compelling, durable superiority or unique safety. Network effects: 0/100. No platform or ecosystem network effects apply.

Cost advantages: 10/100. There is no clear structural cost edge vs. much larger competitors with scale in biologics. Efficient scale: 15/100. Lichen planus and select derm indications may be niches, but still competitive.

Overall durability risk is elevated given intense competition in AD and asthma, and the emergence of multi‑pathway biologics such as Pfizer’s trispecific antibody that targets IL‑4, IL‑13 and TSLP and has reported positive Phase 2 results. Weighted global moat score is 25/100.